KRAS and neoplasm: Importantly, our established tumor models and patient data reveal that in advanced disease, differences in KRAS mutant isoform-specific potency are no longer evident, mirroring findings from previous large cohort studies which failed to support KRAS-mutant allele-specific differences in outcomes [8, 51, 52].